{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:33:40Z","timestamp":1792290820988,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03869-0","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:49:19Z","timestamp":1749628159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in ovarian carcinoma: where do we stand today? A comprehensive review and clinical insights from a leading oncology center in India"],"prefix":"10.1186","volume":"23","author":[{"given":"M D","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Solomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyam","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babul","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"issue":"1","key":"3869_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3869_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3869_CR3","doi-asserted-by":"publisher","unstructured":"Bhatt A, Yonemura Y, Mehta S, et al. Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease?.\u00a0Eur J Surg Oncol. 2020;46(4 Pt A):582\u2013589. https:\/\/doi.org\/10.1016\/j.ejso.2019.11.495.","DOI":"10.1016\/j.ejso.2019.11.495"},{"key":"3869_CR4","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.2174\/138161212802002616","volume":"18","author":"S Mulier","year":"2012","unstructured":"Mulier S, Claes J-P, Dierieck V, Amiel J-O, Pahaut J-P, et al. Survival Benefit of Adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the Different Time-points of Treatment of Ovarian Cancer: Review of Evidence. Curr Pharm Des. 2012;18:3793\u2013803.","journal-title":"Curr Pharm Des"},{"issue":"8","key":"3869_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","volume":"33","author":"NS Horowitz","year":"2015","unstructured":"Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33(8):937\u201343. https:\/\/doi.org\/10.1200\/JCO.2014.56.3106.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3869_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg"},{"key":"3869_CR7","doi-asserted-by":"publisher","unstructured":"Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY; HIPEC for Ovarian Cancer Collaborators. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surg. 2022;157(5):374\u2013383. https:\/\/doi.org\/10.1001\/jamasurg.2022.0143. PMID: 35262624; PMCID: PMC8908225.","DOI":"10.1001\/jamasurg.2022.0143"},{"key":"3869_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, et al. Peritoneal Carcinomatosis Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Advanced Ovarian Carcinoma: A French Multicentre Retrospective Cohort Study of 566 Patients. Eur J Surg Oncol. 2013;39:1435\u201343.","journal-title":"Eur J Surg Oncol"},{"key":"3869_CR9","doi-asserted-by":"publisher","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","volume":"3","author":"Z Lei","year":"2020","unstructured":"Lei Z, Wang Y, Wang J, Wang K, Tian J, Zhao Y, Chen L, Wang J, Luo J, Jia M, et al. Evaluation of Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. JAMA Netw Open. 2020;3:e2013940.","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"3869_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s13193-023-01747-3","volume":"14","author":"SP Somashekhar","year":"2023","unstructured":"Somashekhar SP, Ramya Y, Ashwin KR, et al. Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval\u2014ISPSM Collaborative Study. Indian J Surg Oncol. 2023;14(Suppl 1):226\u201332. https:\/\/doi.org\/10.1007\/s13193-023-01747-3.","journal-title":"Indian J Surg Oncol"},{"key":"3869_CR11","doi-asserted-by":"publisher","first-page":"6010","DOI":"10.3390\/cancers14236010","volume":"14","author":"D Marrelli","year":"2022","unstructured":"Marrelli D, Ansaloni L, Federici O, Asero S, Carbone L, Marano L, Baiocchi G, Vaira M, Coccolini F, Di Giorgio A, et al. Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes. Cancers. 2022;14:6010. https:\/\/doi.org\/10.3390\/cancers14236010.","journal-title":"Cancers"},{"key":"3869_CR12","doi-asserted-by":"publisher","unstructured":"Koole S, van Stein R, Sikorska K, Barton D, Perrin L, etal, OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020;30(6):888\u2013892. https:\/\/doi.org\/10.1136\/ijgc-2020-001231.","DOI":"10.1136\/ijgc-2020-001231"},{"key":"3869_CR13","doi-asserted-by":"publisher","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7(5):100586. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100586.","DOI":"10.1016\/j.esmoop.2022.100586"},{"key":"3869_CR14","doi-asserted-by":"crossref","unstructured":"Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et\u00a0al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378(3):230\u201340.","DOI":"10.1056\/NEJMoa1708618"},{"key":"3869_CR15","doi-asserted-by":"publisher","unstructured":"S Lot Aronson, Marta Lopez-Yurda, Simone N Koole, Prof Jules H Schagen van Leeuwen, Hendrick WR Schreuder et al, Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC 1): final survival analysis of a randomised, controlled phase 3 trial, The Lancet Oncology, 2023, Vol 24 (10) p 1109\u20131118. https:\/\/doi.org\/10.1016\/S1470-2045(23)00396-0.","DOI":"10.1016\/S1470-2045(23)00396-0"},{"key":"3869_CR16","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","volume":"29","author":"CCP Antonio","year":"2022","unstructured":"Antonio CCP, Alida GG, Elena GG, Roc\u00edo GS, Jer\u00f3nimo MG, Luis ARJ, An\u00edbal ND, Francisco BV, Jes\u00fas GR\u00c1, Pablo RR, et al. Cytoreductive Surgery with or without HIPEC after Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Ann Surg Oncol. 2022;29:2617\u201325.","journal-title":"Ann Surg Oncol"},{"key":"3869_CR17","doi-asserted-by":"publisher","first-page":"101523","DOI":"10.1016\/j.suronc.2021.101523","volume":"37","author":"D Marrelli","year":"2021","unstructured":"Marrelli D, Petrioli R, Cassetti D, D\u2019Ignazio A, Marsili S, Mazzei MA, Lazzi S, Roviello F. A Novel Treatment Protocol with 6 Cycles of Neoadjuvant Chemotherapy Followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Stage III Primary Ovarian Cancer. Surg Oncol. 2021;37:101523.","journal-title":"Surg Oncol"},{"issue":"5","key":"3869_CR18","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1245\/s10434-024-15042-0","volume":"31","author":"V Ghirardi","year":"2024","unstructured":"Ghirardi V, Trozzi R, Scanu FR, Giannarelli D, Santullo F, Costantini B, Naldini A, Panico C, Frassanito L, Scambia G, Fagotti A. Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes. Ann Surg Oncol. 2024;31(5):3350\u201360. https:\/\/doi.org\/10.1245\/s10434-024-15042-0.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"3869_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100098","volume":"6","author":"H El Hajj","year":"2021","unstructured":"El Hajj H, Vanseymortier M, Hudry D, Bogart E, Abdeddaim C, et al. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery. ESMO Open. 2021;6(2): 100098. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100098.","journal-title":"ESMO Open"},{"key":"3869_CR20","doi-asserted-by":"publisher","unstructured":"Ansaloni L, De Iaco P, Frigerio L. Re: \"cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase II trial.\" - Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer, the CHORINE study. Gynecol Oncol. 2012;125(1):279\u201381. https:\/\/doi.org\/10.1016\/j.ygyno.2012.01.001.","DOI":"10.1016\/j.ygyno.2012.01.001"},{"key":"3869_CR21","doi-asserted-by":"crossref","unstructured":"Ray MD, Deo SVS, Pramanik R, Premanand N. An intensive audit on 250 patients of advanced ovarian cancer to improve quality of care in a tertiary referral oncology centre in India Int J Reprod Contracept Obstet Gynecol. 2022;11(10):2723\u20132728.","DOI":"10.18203\/2320-1770.ijrcog20222468"},{"key":"3869_CR22","doi-asserted-by":"crossref","unstructured":"Fagotti A, Costantini B, Vizzielli, Perelli F, Ercoli A, Gallotta V, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122:221\u2013225.","DOI":"10.1016\/j.ygyno.2011.04.008"},{"key":"3869_CR23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study. Ann Surg Oncol. 2015;22:1570\u20135. https:\/\/doi.org\/10.1245\/s10434-014-4157-9.","journal-title":"Ann Surg Oncol"},{"key":"3869_CR24","doi-asserted-by":"crossref","unstructured":"Classe\u00a0J,\u00a0Meeus\u00a0P,\u00a0Leblanc\u00a0E, et al #876\u2005Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the chipor randomised phase III trial, International Journal of Gynecologic Cancer\u00a02023;33:A29.","DOI":"10.1136\/ijgc-2023-ESGO.43"},{"key":"3869_CR25","doi-asserted-by":"publisher","unstructured":"Mukur Dipi Ray, Kunal Dhall, Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the management of peritoneal surface malignancies \u2013 An evidence-based review, Current Problems in Cancer, Volume 45, Issue 6, 2021, https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100737.","DOI":"10.1016\/j.currproblcancer.2021.100737"},{"issue":"Suppl 1","key":"3869_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s13193-023-01746-4","volume":"14","author":"SVS Deo","year":"2023","unstructured":"Deo SVS, Ray MD, Kumar L, et al. Pattern of Care in Real-World Scenario on Advanced Epithelial Ovarian Cancer in a Tertiary Referral Oncology Centre in India \u2014 ISPSM Collaborative Study. Indian J Surg Oncol. 2023;14(Suppl 1):233\u20139. https:\/\/doi.org\/10.1007\/s13193-023-01746-4.","journal-title":"Indian J Surg Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03869-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03869-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03869-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:49:21Z","timestamp":1749628161000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03869-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3869"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03869-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6138215\/v1","asserted-by":"object"}]},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Ethics clearance was obtained from from Institutional Ethics clearance, AIIMS, New Delhi.Following the clearance, this retrospective study was conducted, utilizing our prospectively maintained ovarian cancer database at the Department of Surgical Oncology, Dr. BRA-IRCH, AIIMS, New Delhi","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}